



**TARGET PRODUCT PROFILE**  
for a gambiense human  
African trypanosomiasis test  
to identify individuals to  
receive widened treatment



World Health  
Organization



# **TARGET PRODUCT PROFILE**

for a **gambiense human African  
trypanosomiasis** test to identify individuals to  
receive widened treatment



**World Health  
Organization**

Target product profile for a gambiense human African trypanosomiasis test to identify individuals to receive widened treatment

ISBN 978-92-4-004329-9 (electronic version)

ISBN 978-92-4-004330-5 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Target product profile for a gambiense human African trypanosomiasis test to identify individuals to receive widened treatment. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# Contents

Process of document development	iv
Acknowledgements	iv
1. Background	1
2. Use case	1
3. Technical scope	1
4. Medical need	2
5. Target product profile (TPP)	3

## Process of document development

The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was formed, and different subgroups were created to advise on specific NTDs, including a subgroup working on the human African trypanosomiasis (HAT) diagnostic innovation needs. This group of independent experts included leading scientists, public health officials and endemic-country end-user representatives. Standard WHO Declaration of Interest procedures were followed. A landscape analysis of the available products and of the development pipeline was conducted, and the salient areas with unmet needs were identified. Through meetings and remote consultations, the subgroup developed use-cases for the hypothetical tools considered as the main gaps, and gave them an order of priority. A template adapted to the HAT context was agreed and used for the development of HAT TPPs. The draft of this TPP (rated as priority N° 2) underwent several rounds of review by the subgroup members. The ensuing version was reviewed by the DTAG members. Draft version 0.1 was posted on the WHO website for public consultation for 28 days with a proforma comment form.

## Acknowledgements

WHO gratefully acknowledges the independent experts that provided input throughout the TPP development process. Special thanks are due to the NTD DTAG human African trypanosomiasis Sub-Group members Veerle Lejon, Philippe Büscher, Joseph Ndungu'u, Dieudonné Mumba, Vincent Jamonneau and Enock Matovu (Chair) as well as invited expert participants as observers: Paul Verlé and Nick Van Reet. Thanks are also due to members of the NTD DTAG for guidance. WHO staff members Daniel Argaw Dagne, Jonathan King, Jose Ramon Franco, Gerardo Priotto, Pere Simarro, Dieudonné Sankara, Augustin Kadima Ebeja and Anthony Solomon gave support and input to the TPP development process.

# 1. Background

Human African Trypanosomiasis (HAT) is a life-threatening parasitic infection transmitted by the tsetse fly, that is endemic in Sub-Saharan Africa. Having caused devastating epidemics during the 20th century, its incidence has fallen to historically low levels thanks to sustained and coordinated efforts over the past 20 years. Two trypanosome subspecies cause the disease, with distinct epidemiology: *Trypanosoma brucei rhodesiense* (*Tbr*), found in eastern and southern Africa, is harboured by wild and domestic animals which constitute its reservoir, being transmitted occasionally to humans; and *Trypanosoma brucei gambiense* (*Tbg*), in western and central Africa, with humans as the main reservoir, accounting for about 95% of the total caseload.

HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for *Tbg* and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predictive value of serological tests is particularly low. Field-applicable tools include the card agglutination test for trypanosomiasis (CATT) used mainly in active screening by specialized mobile teams, and the rapid diagnostic tests that are more suitable for individual testing at point-of-care. Parasitological confirmation of *Tbg* infection requires microscopic examination of body fluids through laborious methods performed by skilled personnel. The best performing parasitological tests reach 85-95% diagnostic sensitivity at best but are more complex than tests with lower sensitivity.

In gambiense HAT (g-HAT) it has been observed since long that repeated rounds of serological screening followed by treatment of cases detected can bring down the prevalence to low levels, and this has been the cornerstone strategy of g-HAT control and elimination. But it is known that among seropositive but microscopically unconfirmed individuals there is a variable proportion that harbours the parasite and could perpetuate the reservoir. It has not been possible so far to recommend treatment on the basis of suspicion alone, because current treatments are logistically challenging and not sufficiently safe. The expected advent of a safer and easy-to-use treatment, would favourably tip the benefit-risk balance and allow for treating highly suspected individuals (widened treatment). A simple diagnostic tool to identify individuals eligible for treatment would be the ideal complement for a powerful elimination approach.

## 2. Use case

Diagnostic tool to identify individuals with suspected but microscopically unconfirmed g-HAT infection, eligible for treatment with safe and easy-to-use medicines.

## 3. Technical scope

It could be any method of high sensitivity but simple enough to be applicable at the point-of care. The sensitive parasitological methods currently used to confirm a *Tbg* infection are complex because they require specialized materials and equipment for concentrating the parasites, which often depend on a source of electricity, and which are often unavailable at the point-of care in HAT endemic regions. In the future, easier parasitological methods could arise.

The envisioned tool could be in any format, as long as it is simple and requires minimal specialized training.

---

<sup>1</sup> Peripheral health facilities: usually of low sophistication, located in the midst of, or at short distance from, communities at risk of HAT.

## 4. Medical need

The safety profile and administration characteristics of the medicines currently available are not appropriate for their extended use in suspected but parasitologically unconfirmed cases. With the possible advent of a safe, effective and simpler anti-trypanosome treatment, it would be conceivable to widen the criteria of eligibility for treatment, to include individuals without parasitological confirmation but with a high degree of suspicion of harbouring parasites. Such type of “widened treatment” intervention would benefit infected individuals for whom the current diagnostic methods fail to confirm the infection. Simultaneously, it would benefit the community by further suppressing certain parasite reservoirs that perpetuate the risk of transmission.

The needed tool should identify individuals with a high degree of suspicion of infection (independently of symptoms) that can be considered sufficient to justify treatment with a medicine that has a good safety profile.

Ideally, with one test it should be possible to reach a therapeutic decision. A tandem of two simple sequential tests would also be acceptable.

Ideally, the test should be usable in peripheral health facilities<sup>1</sup>, and in mobile labs at village level in zero infrastructure conditions.

A test fulfilling this profile, thought in relation to a safe and easy-to-use medicine that is expected to emerge with time, would nonetheless have a significant role even in the absence of such medicine.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23295](https://www.yunbaogao.cn/report/index/report?reportId=5_23295)

